{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:43:15Z","timestamp":1791193395891,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T00:00:00Z","timestamp":1373587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T00:00:00Z","timestamp":1373587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Novartis Pharma AG (Basel, Switzerland)","award":["NCT00986414"],"award-info":[{"award-number":["NCT00986414"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13\u2010week, double\u2010blind, placebo\u2010controlled study. Patients with Parkinson's disease and moderate\u2010to\u2010severe levodopa (\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa)\u2010induced dyskinesia who were receiving stable\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa\/anti\u2010parkinsonian treatment and were not currently receiving amantadine were randomized to receive either AFQ056 (at doses of 20, 50, 100, 150, or 200 mg daily) or placebo (1:1:1:1:2:3 ratio) for 12 weeks. The primary outcome was the modified Abnormal Involuntary Movements Scale. Secondary outcomes included the 26\u2010item Parkinson's Disease Dyskinesia Scale, the Patient's\/Clinician's Global Impression of Change, and the Unified Parkinson's Disease Rating Scale parts III (motor evaluation) and IV (severity of motor complications). Safety was assessed. In total, 98 of 133 (73.7%) AFQ056\u2010treated patients and 47 of 64 (73.4%) patients in the placebo group completed the study. Baseline characteristics were comparable. Patients randomized to AFQ056 200 mg daily administered in 2 doses demonstrated significant improvements at Week 12 on the modified Abnormal Involuntary Movements Scale compared with placebo (difference, \u22122.8; 95% confidence interval [CI], \u22125.2, \u22120.4;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.007). Based on final actual doses, there was a dose\u2010response relationship on the modified Abnormal Involuntary Movements Scale, with 200 mg daily demonstrating the most robust effect (difference, \u22123.6; 95% CI, \u22127.0, \u22120.3;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012). Improvements in dyskinesia were supported by change on Unified Parkinson's Disease Rating Scale part IV item 32 (50 mg daily: difference, \u22120.7; 95% CI, \u22121.1, \u22120.2;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.003; 200 mg daily: difference, \u22120.5; 95% CI, \u22120.8, \u22120.1;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005). No significant changes were observed on the 26\u2010item Parkinson's Disease Dyskinesia Scale, the Unified Parkinson's Disease Rating Scale part IV item 33 or items 32 and 33, or the Patient's\/Clinician's Global Impression of Change. Unified Parkinson's Disease Rating Scale part III scores were not significantly changed, indicating no worsening of motor symptoms. The most common adverse events (with incidence greater with AFQ056 than with placebo) were dizziness, hallucination, fatigue, nasopharyngitis, diarrhea, and insomnia. AFQ056 demonstrated anti\u2010dyskinetic efficacy in this population without worsening underlying motor symptoms. These results will guide dose selection for future clinical trials. \u00a9 2013 International Parkinson and Movement Disorder Society\n                  <\/jats:p>","DOI":"10.1002\/mds.25561","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T11:04:41Z","timestamp":1373627081000},"page":"1838-1846","source":"Crossref","is-referenced-by-count":126,"title":["AFQ056 in Parkinson patients with levodopa\u2010induced dyskinesia: 13\u2010week, randomized, dose\u2010finding study"],"prefix":"10.1002","volume":"28","author":[{"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) CIC9302\u2010UMR825 and Departments of Neurosciences and Clinical Pharmacology Toulouse University Hospital and University of Toulouse III Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Destee","sequence":"additional","affiliation":[{"name":"Lille North of France University, Lille University Hospital, Movement Disorders Unit INSERM U837 Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Neurology, Juntendo University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Neurology University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[{"name":"Edmond J. Safra Program in Parkinson's Disease Toronto Western Hospital, University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stacy","sequence":"additional","affiliation":[{"name":"Department of Neurology School of Medicine Duke University Medical Center Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tolosa","sequence":"additional","affiliation":[{"name":"Neurology Service, Hospital Clinic, Barcelona, Spain; Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain; Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Nagel","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merschhemke","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Graf","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kenney","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[{"name":"Paracelsus\u2010Elena\u2010Klinik Kassel Department of Neurosurgery University Medical Center of Goettingen Goettingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20458"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20279"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23829"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199310000-00004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00018-5"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.02.005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.07.014"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04456.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.166629"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23616"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20213"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_8_17_1","unstructured":"GuyW.ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication no. ADM 76\u2013338). Rockville MD: US Department of Health Education and Welfare; Public Health Service; Alcohol Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch; Division of Extramural Research Programs; 1976:534\u2013537."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090103"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000266669.18308.af"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20248"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000229546.81245.7F"},{"key":"e_1_2_8_23_1","volume-title":"Multilingual Aphasia Examination","author":"Benton A","year":"1994"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21696"},{"key":"e_1_2_8_25_1","unstructured":"GoetzC StebbinsG ChungK et al.Which dyskinesia scale best detects treatment response? A double\u2010blind placebo controlled multicenter trial using multiple dyskinesia outcome measures. Paper presented at: 16th International Congress of Parkinson's Disease and Movement Disorders; June 17\u201321 2012; Dublin Ireland."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25561","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.25561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:54:47Z","timestamp":1786629287000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,12]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/mds.25561"],"URL":"https:\/\/doi.org\/10.1002\/mds.25561","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,12]]}}}